openPR Logo
Press release

Aytu BioScience, Inc. (NASDAQ: AYTU) Investor Investigation over possible Securities Laws Violations

05-05-2020 10:17 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Aytu BioScience, Inc. (NASDAQ: AYTU) shares over potential securities laws violations.

An investigation for investors in Aytu BioScience, Inc. (NASDAQ: AYTU) shares over potential securities laws violations.

An investigation was announced concerning potential securities laws violations by Aytu BioScience, Inc. in connection with certain financial statements.

Investors who purchased shares of Aytu BioScience, Inc. (NASDAQ: AYTU), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Aytu BioScience, Inc. (NASDAQ: AYTU regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Englewood, CO based Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. Aytu BioScience, Inc. reported that its Total Revenue rose from $3.66 million for the 12 months period that ended on June 30, 2018 to $7.32 million for the 12 months period that ended on June 30, 2019 and that its Net Loss increased from $10.18 million to $27.13 milion over those respective time periods.

Shares of Aytu BioScience, Inc. (NASDAQ: AYTU) declined from $2.47 per share in April 2019 to as low as $0.34 per share on March 9, 2020

Those who purchased shares of Aytu BioScience, Inc. (NASDAQ: AYTU) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Aytu BioScience, Inc. (NASDAQ: AYTU) Investor Investigation over possible Securities Laws Violations here

News-ID: 2035250 • Views: 5475

More Releases from Shareholders Foundation

Investigation for Long-Term investors in NASDAQ: KNDI shares over possible Wrong …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Kandi Technologies Group Inc. Investors who are current long term investors in Kandi Technologies Group Inc (NASDAQ: KNDI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: KNDI stocks follows a lawsuit filed
Investigation for Long-Term Investors in shares of Kirby Corporation (NYSE: KEX) …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kirby Corporation. Investors who purchased shares of Kirby Corporation (NYSE: KEX) s have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Kirby Corporation directors breached their fiduciary duties and caused damage to the company and its shareholders. Houston, TX based
Investigation announced for Investors in shares of Builders FirstSource, Inc. (N …
An investigation was announced concerning whether the takeover of Builders FirstSource, Inc. is unfair to NASDAQ: BLDR stockholders. Investors who purchased shares of Builders FirstSource, Inc. (NASDAQ: BLDR) and currently hold any of those NASDAQ: BLDR shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain officers and directors of Builders FirstSource, Inc. breached their
Investigation for Investors in ANSDAQ: ENDP over possible Wrongdoing at Endo Int …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Endo International plc. Investors who are current long term investors in Endo International plc (NASDAQ: ENDP) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: ENDP stocks follows a lawsuit filed against Endo

All 5 Releases


More Releases for Aytu

GABA Receptor Agonist Market Astonishing Growth | Top Competitors like Sanofi, M …
"Data Bridge Market Research presents a detailed picture of the Global GABA Receptor Agonist Market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers." Data Bridge Market Research has recently added
Investigation for Investors in NASDAQ: AYTU shares over possible Wrongdoing at A …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Aytu BioScience, Inc. Investors who purchased shares of Aytu BioScience, Inc. (NASDAQ: AYTU) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Aytu BioScience directors breached their fiduciary duties and caused damage to the company and its shareholders. Englewood, CO
Cough Suppressant Drugs Market Growth Analysis, Competitor Landscape with Top Pl …
n March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Approval and launch of such new drugs in the market is expected to drive the cough suppressant drugs market growth over the forecast
Cough Suppressant Drugs Market Development Industry 2019 Featuring with Top Play …
In March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Approval and launch of such new drugs in the market is expected to drive the cough suppressant drugs market growth over the forecast
Cough Suppressant Drugs Market Upcoming Opportunities, Growth, Scope Analysis by …
Cough suppressant drugs are used to suppress the cough. Cough is usually doesn't require any treatment as it goes away in few days. However cough medicines are required if it persists for more than a week and if it starts disturbing routine activities. Also, some types of cough help in clearing patients lungs and hence should not be treated with cough suppressant drugs. Hence consultation with the doctor before consumption
Male Infertility Treatment Market Covering Prime Factors and Competitive Outlook …
The demand for Male Infertility Treatment Market is anticipated to be high for the next few years. By considering this demand we provide latest Male Infertility Treatment Market Report which gives complete industry analysis, market outlook, size, growth and forecast till 2023. This report will assist in analyzing the current and future business trends, sales and revenue forecasts. Global Male Infertility Treatment Market Overview: This report studies the Global Male Infertility Treatment